Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment
- PMID: 27481548
- DOI: 10.1002/hep.28744
Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment
Abstract
The presence of an intrahepatic cholangiocarcinoma (iCCA) in a cirrhotic liver is a contraindication for liver transplantation in most centers worldwide. Recent investigations have shown that "very early" iCCA (single tumors ≤2 cm) may have acceptable results after liver transplantation. This study further evaluates this finding in a larger international multicenter cohort. The study group was composed of those patients who were transplanted for hepatocellular carcinoma or decompensated cirrhosis and found to have an iCCA at explant pathology. Patients were divided into those with "very early" iCCA and those with "advanced" disease (single tumor >2 cm or multifocal disease). Between January 2000 and December 2013, 81 patients were found to have an iCCA at explant; 33 had separate nodules of iCCA and hepatocellular carcinoma, and 48 had only iCCA (study group). Within the study group, 15/48 (31%) constituted the "very early" iCCA group and 33/48 (69%) the "advanced" group. There were no significant differences between groups in preoperative characteristics. At explant, the median size of the largest tumor was larger in the "advanced" group (3.1 [2.5-4.4] versus 1.6 [1.5-1.8]). After a median follow-up of 35 (13.5-76.4) months, the 1-year, 3-year, and 5-year cumulative risks of recurrence were, respectively, 7%, 18%, and 18% in the very early iCCA group versus 30%, 47%, and 61% in the advanced iCCA group, P = 0.01. The 1-year, 3-year, and 5-year actuarial survival rates were, respectively, 93%, 84%, and 65% in the very early iCCA group versus 79%, 50%, and 45% in the advanced iCCA group, P = 0.02.
Conclusion: Patients with cirrhosis and very early iCCA may become candidates for liver transplantation; a prospective multicenter clinical trial is needed to further confirm these results. (Hepatology 2016;64:1178-1188).
© 2016 by the American Association for the Study of Liver Diseases.
Comment in
-
Reply.Hepatology. 2017 May;65(5):1778. doi: 10.1002/hep.28993. Epub 2017 Mar 30. Hepatology. 2017. PMID: 27997680 No abstract available.
-
Strategies to improve survival of patients with intrahepatic cholangiocarcinoma undergoing liver transplantation.Hepatology. 2017 May;65(5):1777-1778. doi: 10.1002/hep.28994. Epub 2017 Feb 3. Hepatology. 2017. PMID: 27997682 No abstract available.
-
Intrahepatic cholangiocarcinoma arising from HBV infection may be a highly selected population for liver transplantation.Hepatology. 2017 Nov;66(5):1703-1704. doi: 10.1002/hep.29413. Epub 2017 Sep 29. Hepatology. 2017. PMID: 28759704 No abstract available.
-
Reply.Hepatology. 2017 Nov;66(5):1704-1705. doi: 10.1002/hep.29412. Epub 2017 Sep 29. Hepatology. 2017. PMID: 28759706 No abstract available.
-
Liver transplantation for the solitary intrahepatic cholangiocarcinoma less than 2 cm in diameter.Hepatobiliary Surg Nutr. 2017 Oct;6(5):332-334. doi: 10.21037/hbsn.2017.05.10. Hepatobiliary Surg Nutr. 2017. PMID: 29152481 Free PMC article. No abstract available.
-
Should we expand liver transplant criteria to cirrhotic patients with intrahepatic cholangiocarcinoma?Hepatobiliary Surg Nutr. 2017 Oct;6(5):335-338. doi: 10.21037/hbsn.2017.07.01. Hepatobiliary Surg Nutr. 2017. PMID: 29152482 Free PMC article. No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources